NYU Langone

 

Videos
19:29

NYU Langone

Long-Term Efficacy of Ibrutinib in CLL

FEATURING Marc Braunstein
  • 67 views
  • October 6, 2024
12:22

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "KEYNOTE-942 Trial - 3-Year Update on mRNA-4157 & Pembro in Resected Melanoma"

FEATURING Jeffrey Weber
  • 223 views
  • June 12, 2024
  • 1
13:06

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "ECOG-ACRIN E4412 Study of Ipi, Nivo, and Brentuximab Vedotin in Pts With R/R cHL"

FEATURING Catherine Diefenbach
  • 24 views
  • December 17, 2023
14:55

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Response Adapted Therapy in cHL

FEATURING Catherine Diefenbach
  • 30 views
  • October 17, 2023
06:34

NYU Langone

Considerations for Reusing Drugs in Later Stages of MM

FEATURING Faith Davies
  • 122 views
  • October 17, 2023
  • 1
21:16

GRACE

Targeted Therapies in Lung Cancer 2023: Translating Cancer Discovery - Targeting KRAS G12C in NSCLC

FEATURING Joshua Sabari
  • 150 views
  • August 25, 2023
  • 1
20:30

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "New Therapies for SCLC"

FEATURING Sally C. M. Lau
  • 307 views
  • June 15, 2023
  • 1
16:00

AACR 2023 Conference Coverage

A Personalized Cancer Vaccine mRNA-4157 + Pembro vs. Pembro in Resected HR-Melanoma: Efficacy & Safety Results From the Randomized, Open-Label Phase 2 mRNA-4157-P201/KEYNOTE-942 Trial

FEATURING Jeffrey Weber
  • 341 views
  • May 9, 2023
  • 2
07:45

ecancer

Latest Treatments in Esophageal Cancer

FEATURING Costas Bizekis
  • 90 views
  • May 9, 2023
21:26

NYU Langone

Common TKI Toxicity Management in 2L HCC Treatment

FEATURING Jennifer Wu
  • 415 views
  • May 4, 2023
  • 1
04:53

SGO 2023 Conference Coverage on VuMedi

SGO 2023 Updates on Advanced or Recurrent Endometrial Tumors: NGS Complements Conventional Clinical HER2 Testing

FEATURING Sarah Lee
  • 87 views
  • April 14, 2023
12:04

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Preliminary Efficacy and Correlative Results of the Phase II Trial HCRN GI16-288: Perioperative CV301 Vaccination in Combination With Nivo and Systemic Chemo for Resectable Hepatic-Limited mCRC

FEATURING Kristen Spencer
  • 96 views
  • February 23, 2023
10:29

NYU Langone

FDA Approval of Adagrasib in KRAS G12Cm NSCLC

FEATURING Joshua Sabari
  • 676 views
  • December 16, 2022
  • 5
20:08

NYU Langone

Treatment Questions for Medical Oncologists Treating Melanoma

FEATURING Jeffrey Weber
  • 383 views
  • November 18, 2022
15:30

NYU Langone

TPO-RA Agents in Children With ITP: What to Consider in Terms of Timing and Rationale

FEATURING Kirsty Hillier
  • 59 views
  • October 11, 2022
  • 1
22:51

NYU Langone

Case Presentation on HER2+ Breast Cancer: Adapting Patient Care to a Rapidly Evolving Treatment Landscape

FEATURING Douglas Marks
  • 259 views
  • September 13, 2022
  • 1
17:41

NYU Langone

The Great Debate: Is Neoadjuvant Therapy Really Better Than Adjuvant Therapy in Melanoma?

FEATURING Jeffrey Weber
  • 344 views
  • September 23, 2021
24:32

NYU Langone

Adjuvant and Neoadjuvant Melanoma Dilemmas: Considering Treatment Outcomes With IO and Targeted Therapy Agents

FEATURING Jeffrey Weber
  • 388 views
  • May 20, 2021
  • 1
14:08

NYU Langone

2020 CheckMate 238 Update on IO in Advanced Stage Melanoma: Did Nivo Show Sustained Superior Patient Benefit vs. Ipi in High-Risk Resected Disease?

FEATURING Jeffrey Weber
  • 1,145 views
  • November 9, 2020
  • 2